News and Trends 22 Feb 2018
GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II
One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures. GW Pharma wants to use cannabinoid drugs to treat conditions like autism and epilepsy. However, one of its drug candidates, GWP42006, has slipped up in a Phase […]